Cornea

Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye disease.

A significant proportion of cataract surgery patients exhibit hyperosmolar tear film both before and 1 month after surgery, underscoring preoperative screening and postoperative management to optimize visual outcomes.

At ARVO 2025, in Salt Lake City, Utah, Anisha Kasi talked about her presentation on how her team used the TriNetX database, a large database of over 150 million patients worldwide, to validate the connection between hidradenitis suppurativa and inflammatory eye conditions.

Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its potential as a leading therapy.

A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization of arcuate keratotomy planning

Ellen Koo, MD, presented data from first in-human clinical trials, looking at the results from magnetic cell therapy and reports on the efficacy and safety in the patients.

Perfluorohexyloctane demonstrated rapid symptom relief in patients with dry eye, with effects reported as early as 5 minutes after dosing.

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential impacts on vision and ocular health.

Outcomes from high myopia LASIK using the Teneo laser platform demonstrate strong visual stability and patient satisfaction, with reduced dysphotopsias and minimal reliance on cycloplegia or nomograms.

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

A machine learning model using treated astigmatism and other nuanced inputs can significantly improve the accuracy and personalization of arcuate keratotomy planning

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.

The retrospective study assessed corneal cross-linking complications at Wills Eye Hospital from 2018 to 2023.

New research links HPV to thyroid eye disease, suggesting viral infection may trigger immune responses through molecular mimicry, impacting diagnosis and treatment.

George O. Waring IV, MD, FACS, discusses the “vision for a lifetime” approach and how modern advancements allow tailored treatments for every stage of eye maturity.

Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most often affects the choroid (90%), ciliary body (6%), and iris (4%)

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.